the impact of hemophilia inhibitors on patient outcomes
Published 2 years ago • 434 plays • Length 2:27Download video MP4
Download video MP3
Similar videos
-
1:39
therapeutic potential of ides in hemophilia a with inhibitors
-
5:42
improving the qol of patients with hemophilia with inhibitors
-
1:23
the present and future of hemophilia a treatment
-
1:46
unmet needs in hemophilia b: treating patients who develop inhibitors
-
1:27
the impact of emicizumab on the hemophilia treatment landscape
-
1:43
the safety and efficacy of fitusiran prophylaxis in patients with hemophilia a and b
-
17:48
life with hemophilia after gene therapy (from the peruvian amazon) | wfh2022 presentation
-
8:37
primary analysis of haven 7: emicizumab prophylaxis in infants with severe hemophilia a
-
4:36
haemonetics
-
2:38
cardiotoxicity associated with mcl-1 inhibition for r/r hematologic malignancies
-
3:04
fitusiran significantly reduces bleeding events in patients with hemophilia a or b, with inhibitors
-
1:05
promising antibodies being explored in hemophilia & a novel diagnostic tool for patients
-
1:18
unmet needs in hemophilia treatment
-
1:09
highlights from isth: gene therapy in hemophilia a & undiagnosed bleeding disorders in pediatrics
-
4:43
novel treatments being explored for patients with hemophilia: highlights from isth 2024
-
0:44
the role of social media in patient advocacy in hemophilia
-
2:15
emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia a
-
1:48
the promise of fitusiran for the treatment of patients with hemophilia a and b
-
2:49
haven-6 trial updates: emicizumab in non-severe hemophilia a
-
1:41
promising novel approaches for inhibitor suppression in hemophilia
-
0:39
promising therapeutic options emerging in hemophilia